Phase I Clinical Trial R327 Advances to High Dose Cohort
Filed with ASX · · 3 pages · English
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Anti-Viral Patent Granted in Hong Kong
- Positive safety data from 4th Cohort -Phase I Clinical Trial
- $3.08m R&D Rebate Received
- Safety Committee Clears PhI R327 Dose Increase
- S&P DJI Announces March 2022 Quarterly Rebalance
Later from Recce Pharmaceuticals
- Corporate Presentation - Biotech Investor Lunch
- Phase I Clinical Trial R327 Advances to 4000mg
- Phase I Positive Safety Data - 4000mg Complete
- Corporate Presentation - Aussie Equities Day 2022
- Phase I Clinical Trial of R327 I.V. - 6000mg Complete
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals